Correction to: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5608
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan ; day:10 ; month:10 ; year:2022 ; pages:1-2
Prostate cancer and prostatic diseases ; (10.10.2022), 1-2
- Creator
-
Shao, Yu-Hsuan Joni
Hong, Jian-Hua
Chen, Chun-Kai
Huang, Chao-Yuan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41391-022-00596-5
- URN
-
urn:nbn:de:101:1-2022122721143533627289
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Shao, Yu-Hsuan Joni
- Hong, Jian-Hua
- Chen, Chun-Kai
- Huang, Chao-Yuan
- SpringerLink (Online service)
Other Objects (12)
A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression
Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan
Correction to: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan
A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
Effekt eines Gonadotropin-Releasing-Hormon Agonisten auf die Prolaktinsekretion
Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis
Hormonal induction of spawning in 4 species of frogs by coinjection with a gonadotropin-releasing hormone agonist and a dopamine antagonist
Expression von Gonadotropin-Releasing-Hormon und Gonadotropin-Releasing-Hormon-Rezeptor in Endometriose-Gewebe
Expression von Gonadotropin-Releasing-Hormon und Gonadotropin-Releasing-Hormon-Rezeptor in Endometriose-Gewebe
Der Einfluss von Gonadotropin-Releasing-Hormone-Agonisten-Therapie auf den Knochenstoffwechsel von Frauen
A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients
Effekte eines Gonadotropin-Releasing-Hormon-Agonisten auf die Sekretion der Gonadotropine bei jungen Männern
A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression
Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan
Correction to: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan
A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
Effekt eines Gonadotropin-Releasing-Hormon Agonisten auf die Prolaktinsekretion
Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis
Hormonal induction of spawning in 4 species of frogs by coinjection with a gonadotropin-releasing hormone agonist and a dopamine antagonist
Expression von Gonadotropin-Releasing-Hormon und Gonadotropin-Releasing-Hormon-Rezeptor in Endometriose-Gewebe
Expression von Gonadotropin-Releasing-Hormon und Gonadotropin-Releasing-Hormon-Rezeptor in Endometriose-Gewebe
Der Einfluss von Gonadotropin-Releasing-Hormone-Agonisten-Therapie auf den Knochenstoffwechsel von Frauen
A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients
Effekte eines Gonadotropin-Releasing-Hormon-Agonisten auf die Sekretion der Gonadotropine bei jungen Männern
A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression
Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan
Correction to: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan
A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
Effekt eines Gonadotropin-Releasing-Hormon Agonisten auf die Prolaktinsekretion
Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis
Hormonal induction of spawning in 4 species of frogs by coinjection with a gonadotropin-releasing hormone agonist and a dopamine antagonist
Expression von Gonadotropin-Releasing-Hormon und Gonadotropin-Releasing-Hormon-Rezeptor in Endometriose-Gewebe
Expression von Gonadotropin-Releasing-Hormon und Gonadotropin-Releasing-Hormon-Rezeptor in Endometriose-Gewebe
Der Einfluss von Gonadotropin-Releasing-Hormone-Agonisten-Therapie auf den Knochenstoffwechsel von Frauen
A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients